Aprea Therapeutics
APRE
33 hedge funds and large institutions have $1.52M invested in Aprea Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 10 closing their positions.
4,670% more call options, than puts
Call options by funds: $477K | Put options by funds: $10K
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0.09% less ownership
Funds ownership: 0.55% → 0.46% (-0.09%)
18% less funds holding
Funds holding: 40 → 33 (-7)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
66% less capital invested
Capital invested by funds: $4.5M → $1.52M (-$2.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$121K |
| 2 |
Jane Street
New York
|
+$82.9K |
| 3 |
Two Sigma Investments
New York
|
+$48.1K |
| 4 |
D.E. Shaw & Co
New York
|
+$37.9K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$623K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56.9K |
| 4 |
PP
PDT Partners
New York
|
-$55K |
| 5 |
Goldman Sachs
New York
|
-$54K |
APRE Hedge Fund Activity: Q2 2022 in Review
33 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2022, worth a combined $1.52M — down 66% from $4.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of APRE and 4 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Morgan Stanley, adding an estimated $121K. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $623K sold.
- 33 institutional investors held Aprea Therapeutics (APRE) as of Q2 2022, down from 40 in Q1 2022.
- Funds reported $1.52M of Aprea Therapeutics stock for Q2 2022, down 66% quarter-over-quarter.
- 4 funds opened new Aprea Therapeutics positions in Q2 2022 and 10 closed out, a net change of -6 holders.
- The largest Aprea Therapeutics buyer in Q2 2022 was Morgan Stanley, an estimated $121K added.
- The largest Aprea Therapeutics seller in Q2 2022 was Kennedy Capital Management, an estimated $623K sold.
Based on aggregated 13F filings for Q2 2022.